DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026APR-1051 Phase 1 clinical trial
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohortsPatient expansion
Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose
CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of
